Name	Steve OH
Current Position	Independent Cell Therapy Leader
Country	Singapore
Major Field	Cell & Gene Therapy

Educational Background

Ph.D. 1991 – Biochemical Engineering, Birmingham University, UK

B.Sc.Eng (Hons) 1987 – Chemical Engineering, University College London, UK

Professional Experience

1. Inventor of novel bioprocessing solutions such as microcarrier technology, small molecules for differentiation, serum free media and monoclonal antibodies.
2. Developed complex stem cell manufacturing for neural stem cells, heart cells, blood stem cells and red blood cells
3. Strategised and managed multi-disciplinary research programmes across stem cell biology, characterisation, media development, bioprocessing and animal models for stem cells applications.
4. Engagement with over 50 companies for specialised contract research and collaborations.

Other Experience and Professional Memberships

Besides stem cell bioprocessing, I am passionate about education and training. I have set up 3 labs and was the Director of the Bioprocess Internship Programme which trained 200 graduates for the biopharma industry in Singapore from 2010-2015. I am also in leadership positions at the International Society of Cell & Gene Therapy (**ISCT**), International Society of Stem Cell Research (**ISSCR**), International Stem Cell Banking Initiative (**ISCBI**), Global Alliance of iPSC Therapies (**GAiT**) International Stem Cell Banking Initiative (**ISCBI**) and Stem Cell Society, Singapore (**SCSS**).

Selected Scientific Publications (out of 140)

1. An allied reprogramming, selection, expansion, and differentiation platform for creating hiPSC on microcarriers. Lam ATL, Ho V, Vassilev S, Reuveny S, Oh SKW. **Cell Prolif.** 2022. May 19; 55(8): e13256.
2. Strategies to enhance immunomodulatory properties and reduced heterogeneity in mesenchymal stromal cells during ex vivo expansion. Srinivasan A, Sathiyanathan P, Yin L, Liu TM, Lam A, Ravikumar M, Smith RAA, Loh HP, Zhang Y, Ling L, Ng SK, Yang YS, Lezhava A, Hui J, Oh S, Cool SM. **Cytotherapy**. 2022. May; 24(5), 456-472.

3. A scalable suspension culture platform for generating high-density cultures of universal red blood cells from human induced pluripotent stem cells. J. Sivalingam, Y. SuE, Z.R. Lim, A.T.L. Lam, A.P. Lee, H.L. Lim, H.Y. Chen, H.K. Tan, T. Warrier, J.W. Hang, N.B. Nazir, A.H.M. Tan, L. Renia, Y.H. Loh, S. Reuveny, B. Malleret and S.K.W. Oh. **Stem Cell Reports.** 2020 Nov. 27, S2213-6711(20)3045602.